Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 401-420 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 401 | Vantor lowweak | Opp 1 Risk 1 | Thesis: Vantor's membership rationale suggests spatial-intelligence and constellation expansion relevance, but there are no retained evidence or article summaries within the recent evidence window to support a current opportunity thesis. Why now: Why now is weak because the reviewed sources contain no retained post-cutoff directional evidence. Caveats: Coverage debug shows articles after recent evidence window 0 and evidence after recent evidence window 0. Membership rationale references article IDs without and cannot be cited directly here. |
| 402 | Varda Space Industries lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources confirms cohort relevance, but it contains no retained 90-day direct positive evidence to support a durable 1 year+ upside thesis. Why now: No within the recent evidence window company-specific evidence were available after filtering; articles after recent evidence window and evidence after recent evidence window are both zero in coverage data, so recency-based thesis formation is not supported in these reviewed sources. Caveats: 12 articles were considered historically, but zero article IDs remained after the 90-day recent evidence filter. Membership rationale cites older support article IDs but those underlying evidence are not retained in the served reviewed sources. Scores are constrained by evidence absence, not by a documented negative business development. |
| 403 | Venturi Astrolab lowweak | Opp 1 Risk 1 | Thesis: The phase-2 rationale references NASA moon buggy contracts and moon base planning tied to articles: and: which could have supported an opportunity case, but these reviewed sources provide no representative article details, or retained evidence after recent evidence window. Therefore no grounded positive thesis can be advanced here. Why now: Why now is weak because despite 30 articles considered, coverage data shows articles after recent evidence window of 0 and evidence recent evidence review kept_rows of 0, so the reviewed sources does not preserve dated supporting evidence inside the 90-day window. Caveats: Phase-2 rationale cannot substitute for cited article evidence because are absent. No direct positive or negative evidence arrays are populated. Low scores are driven by evidence retention limits in these reviewed sources. |
| 404 | Virgin Galactic Holdings, Inc. lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources does not provide direct positive evidence inside the scoring fields, so no positive investment thesis is supportable here. Why now: The phase2 rationale references three article IDs, but the reviewed sources includes no representative article summaries or evidence to cite for a dated catalyst. Coverage data shows zero article IDs after recent evidence window and zero available evidence, so the current-state thesis is unsupported by reviewed sources detail. Caveats: Do not infer direction from company identity or sector relevance alone. Phase2 membership support cannot substitute for direct thesis evidence. |
| 405 | Vyoma GmbH lowweak | Opp 1 Risk 1 | Thesis: Insufficient admissible reviewed sources evidence to support a positive thesis within the selected recent evidence window, even though membership rationale says Vyoma is an SDA company selected by ESA and flying SSA sensors. Why now: Why now is unsupported because the reviewed sources contain no surviving evidence after recent evidence filtering; timing and business-state changes cannot be validated from the provided material. Caveats: Zero evidence after recent evidence filtering. Membership rationale alone is not sufficient for directional scoring. No direct dated catalyst or adverse development is provided. |
| 406 | Windward Ltd. lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources provide no direct positive company-specific evidence after recent evidence window. The only described context is that Vantor partnered with Windward for maritime awareness, but relations are context-only unless separately gated and cannot be used as counterparty propagation evidence. Why now: No catalyst is established. Coverage debug shows 27 article IDs considered but 0 after recent evidence window and 0 evidence available. Caveats: Membership rationale references article ID: but no is provided in the reviewed sources, so it cannot be cited as factual scoring evidence under the the evidence standard. Relation context is explicitly weaker and not valid counterparty propagation evidence. |
| 407 | WISeKey International Holding Ltd lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources indicates space-related operations through WISeSat, but provides no retained within the recent evidence window direct positive evidence or article to support an opportunity thesis. Why now: There are zero available evidence after recent evidence window for ranking, so no evidence-backed timing signal is available. Caveats: Membership support mentions 21 LEO satellites launched and operational space-related infrastructure, but those claims are not accompanied here by retained ranking evidence or article. Without dated evidence inside the recent evidence window, score should remain low-conviction. |
| 408 | York Space Systems lowweak | Opp 1 Risk 1 | Thesis: The membership rationale references public listing status and defense contract momentum, but no retained within the recent evidence window direct evidence or article summaries are available here to support a positive thesis. Why now: The reviewed sources have no retained dated evidence after the 90-day recent evidence window, so there is no citable timing edge for a 1 year+ ranking. Caveats: Coverage is effectively empty after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. Membership rationale cites article IDs and, but no or retained evidence text are provided here. Later-dated evidence could supersede older listing or contract-status claims, but no such retained evidence exists in these reviewed sources. |
| 409 | York Space Systems lowweak | Opp 1 Risk 1 | Thesis: The membership rationale suggests meaningful satellite-manufacturing and tactical-communications activity, but the reviewed sources retains no direct evidence within the recent evidence window to support a positive thesis. Why now: Although membership support cites articles, and: no representative summaries or retained evidence are included here, leaving no current catalyst basis. Caveats: 54 articles considered, but 0 retained after recent evidence filtering. Cannot elevate based on membership rationale alone. |
| 410 | Akashalabdhi lowweak | Opp 0 Risk 0 | Thesis: No positive thesis is supportable because the reviewed sources contain no direct positive evidence for Akashalabdhi within the recent evidence window. Why now: There is no visible near-term or long-horizon company-specific catalyst in the reviewed sources. The membership review explicitly says the only included article does not mention Akashalabdhi in the visible summary, and coverage debug shows zero articles and zero evidence after recent evidence window. Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article. Evidence recent evidence review shows 0 kept rows after the March 29, 2026 cutoff. The reviewed sources itself says visible evidence is insufficient to determine even qualifying membership. |
| 411 | Amentum Holdings Inc. lowweak | Opp 0 Risk 0 | Thesis: No positive thesis is supportable from retained reviewed sources evidence because there are no direct positive evidence and no articles retained after the 90-day recent evidence window. Why now: No current catalyst is evidenced in the retained reviewed sources. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window despite large historical mention volume. Caveats: Phase-2 rationale references article IDs and, but no article summaries or retained evidence are included here. Historical aerospace exposure does not create a current directional thesis without retained evidence. |
| 412 | Apparition Geoservices GmbH lowweak | Opp 0 Risk 0 | Thesis: No positive thesis can be established because no direct positive evidence for Apparition Geoservices GmbH is available in the reviewed sources after recent evidence filtering. Why now: No current business-state change or catalyst is visible. Although 6 articles were considered, coverage debug shows 0 articles after recent evidence window and 0 evidence after recent evidence window, while the membership review says the reviewed sources are only a broad European tech funding roundup without a direct company-specific description. Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Mention count and article count do not increase conviction because no post-recent evidence window evidence are available. Review-status rationale says retrieval context is insufficient for membership. |
| 413 | Arkeon lowweak | Opp 0 Risk 0 | Thesis: No positive thesis is supported because Arkeon has no direct positive evidence in the reviewed sources within the selected recent evidence window. Why now: No company-specific timing signal is visible. Coverage debug shows zero post-recent evidence window articles and evidence, and the membership note says only a generic funding-roundup article was available without a company-specific description tying Arkeon to the scope. Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article No direct event, fact, or negative development is available after recent evidence window. Low membership confidence is not directional evidence. |
| 414 | Ars Magna Semiconductors lowweak | Opp 0 Risk 0 | Thesis: No positive thesis can be formed because the reviewed sources includes no direct positive evidence for Ars Magna Semiconductors within the recent evidence window. Why now: There is no visible long-horizon strategic catalyst in the usable evidence. Coverage debug shows zero post-recent evidence window articles and evidence, and the only cited support is a general tech funding roundup without a company-specific description linking the company to the scope. Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article No direct positive or adverse operating evidence is available. Generic roundup context is weaker than company-specific evidence and is not directional proof. |
| 415 | Augusta Labs lowweak | Opp 0 Risk 0 | Thesis: No positive thesis is supportable because the reviewed sources have no direct positive evidence for Augusta Labs after recent evidence filtering. Why now: No current or durable catalyst can be identified from the reviewed sources. Coverage debug shows zero post-recent evidence window articles and evidence, and the membership note says the company is only present in a generic funding-roundup article without direct identification against the listed criteria. Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Absence of risk evidence is not positive evidence. No direct company-specific facts or events are available. |
| 416 | BeatpulseLabs lowweak | Opp 0 Risk 0 | Thesis: No positive thesis can be justified because no direct positive evidence for BeatpulseLabs is present in the reviewed sources within the recent evidence window. Why now: There is no visible catalyst or deterioration signal. Coverage debug shows zero post-recent evidence window articles and evidence, and the only cited support is a generic funding-roundup article with no direct company-specific connection to the scope. Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article No direct event or fact evidence is available after recent evidence window. Generic context should not be treated as directional proof. |
| 417 | Bluestaq lowweak | Opp 0 Risk 1 | Thesis: No positive thesis is supported. The reviewed sources say Bluestaq is mentioned only through an executive's prior role at the company, which is indirect context rather than company-specific business evidence (: unavailable in reviewed sources). Why now: There is no clear why-now catalyst because the only reference is an indirect executive-background mention, with no direct event, product, contract, or financing evidence available. Caveats: No current evidence is provided for Indirect mention via an executive's prior role is not direct company evidence. Zero evidence available after recent evidence window. |
| 418 | Bose Corporation lowweak | Opp 0 Risk 0 | Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for Bose Corporation after the 90-day recent evidence window. Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 97 articles considered but 0 articles after recent evidence window and 0 evidence available after dedupe; despite broad article consideration, nothing survived the time/evidence filters for a 1 year+ thesis judgment. Caveats: Phase-2 membership rationale says only a generic funding roundup was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept. |
| 419 | Breaking Change lowweak | Opp 0 Risk 0 | Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for Breaking Change after the 90-day recent evidence window. Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 3 articles considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable. Caveats: Phase-2 membership rationale says the reviewed sources gives no meaningful company-specific evidence and references: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept. |
| 420 | CameraMatics lowweak | Opp 0 Risk 0 | Thesis: No positive thesis can be supported because there is no direct positive evidence for CameraMatics in the reviewed sources after recent evidence filtering. Why now: No company-specific catalyst is visible despite 6 articles considered, because coverage debug shows 0 articles after recent evidence window and 0 evidence after recent evidence window. The membership note says the reviewed sources only includes CameraMatics in a generic funding roundup with no direct statement tying it to the scope. Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Article count does not create conviction because no post-recent evidence window evidence are available. No direct positive or adverse company-specific event is available. |
Risk view
Showing rows 121-140 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 121 | Aalyria Technologies mediumweak | Opp 5 Risk 2 | Thesis: The reviewed sources includes no material negative evidence; the main risk is thin grounding because the conclusion relies on one cited contract-related article without available detail or corroboration. Why now: Current relevance is tied to the cited Space Force Golden Dome contract award context in article, though the reviewed sources omits the and representative article details. Caveats: No article is supplied for the cited support article. Opportunity rests on a single contract-related rationale summary. Contract inclusion alone does not reveal contract size, economics, or conversion pace. |
| 122 | Agnikul lowweak | Opp 3 Risk 2 | Thesis: Risk is moderate because the reviewed sources explicitly says it lacks direct, specific evidence of rocket company operations or a funding/contract event for Agnikul itself in the included material, so the opportunity case is not adequately grounded. Why now: The only timing argument is broad strategic sector positioning in Indian spacetech; there is no validated current catalyst in available evidence. Caveats: Phase-2 rationale references: and: but the reviewed sources does not provide or summaries. Sector beneficiary framing is weaker than direct company event/fact evidence. Coverage debug shows zero evidence after recent evidence window. |
| 123 | Antaris Inc. lowweak | Opp 2 Risk 2 | Thesis: Current ranking risk is mostly uncertainty risk: without retained evidence inside the 90-day window, the reviewed sources does not establish whether the referenced programs are progressing, delayed, funded, or commercially material. Why now: There is no retained 90-day evidence in these reviewed sources despite references to evidence in earlier processing. Recency-sensitive conclusions therefore cannot be made from the local reviewed sources. Caveats: Membership rationale references older evidence but no article IDs are provided with accessible summaries in these reviewed sources body. No representative articles or retained evidence are included. Low score reflects evidence absence, not a negative business judgment. |
| 124 | Apogeo Space lowweak | Opp 4 Risk 2 | Thesis: No material adverse evidence is provided, but the reviewed sources does not show contract economics, execution milestones, or customer traction, so commercialization risk remains. Why now: The reviewed sources' membership rationale cites article: for the integration agreement and technical collaboration, but no article or direct evidence are included. Caveats: Evidence is thin and article-level details are missing. Collaboration and integration agreements are weaker than revenue-bearing customer wins. Single-article support limits conviction. |
| 125 | Arctus Aerospace lowweak | Opp 3 Risk 2 | Thesis: The reviewed sources also explicitly says it is unclear whether Arctus is a true space company versus an atmospheric UAV company. That category ambiguity weakens thesis durability for this specific ranking universe, and no adverse company-specific event is otherwise available. Why now: Funding plus ongoing development could matter over a 1 year+ horizon, but there is no retained dated evidence row to confirm timing, financing close date, or development milestone sequence. Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. The positive case relies on phase2 rationale rather than retained direct event/facts. |
| 126 | Argotec lowweak | Opp 1 Risk 2 | Thesis: The main risk is evidentiary opacity: no kept structured positive or negative rows are available after recent evidence window, so business-state, traction, and durability are uncertain. Why now: Why now is weak because the reviewed sources show zero evidence kept within the 90-day recent evidence window for ranking, and the only cited support is an older membership rationale referring to 7 Hawk microsatellites for Italy's IRIDE constellation aboard a SpaceX launch from article: but no article or dated evidence row is provided in the reviewed sources for ranking use. Caveats: No article is provided for the membership support article: so it cannot be cited as a factual ranked-evidence item under the the evidence standard. Coverage debug shows zero evidence after recent evidence window. Private/public status is not used as a filter and is unclear from these reviewed sources. |
| 127 | Astranis lowmedium | Opp 4 Risk 2 | Thesis: The evidence is mostly supporting article context rather than strong company-specific event extraction, so execution and conversion risk remain, but there is no direct adverse evidence available. Why now: Recent dated context within the 90-day recent evidence window points to fresh financing and government program inclusion, both relevant for a 1 year+ horizon: Andromeda context on April 8, 2026 and funding context on June 19, 2026 Evidence
Caveats: Evidence is mainly supporting article context, which is weaker than direct event/fact evidence. An older 2025 article about a 2027 transportation deal exists, but it is outside the recent evidence window and not used as current proof. |
| 128 | Astranis Space Technologies lowweak | Opp 2 Risk 2 | Thesis: There is no direct adverse evidence, but the ranking is constrained by zero retained evidence after recent evidence window and potential duplication concerns in the broader article set. Why now: The current batch retains no representative articles or evidence within the 90-day recent evidence window for Astranis, so the reviewed sources does not provide a current dated catalyst despite the phase-2 rationale. Caveats: No retained evidence after recent evidence window. Phase-2 rationale mentions duplicate article versions; duplicates would not be independent confirmation anyway. |
| 129 | Astrobotic Technology lowweak | Opp 2 Risk 2 | Thesis: No material adverse evidence is available in the reviewed sources, so a negative thesis is unsupported. Why now: The rationale references articles, and: but no corresponding available evidence remains available for direct scoring after recent evidence filtering. Caveats: Lunar lander category fit does not equal thesis attractiveness. Coverage debug shows zero available evidence after recent evidence window. Without direct execution, funding, contract-conversion, or mission-status evidence, scores should remain conservative. |
| 130 | Astrolight UAB lowweak | Opp 2 Risk 2 | Thesis: The key risk is that the only described support is partner context, and the reviewed sources explicitly notes the relation row is context-only, leaving no strong basis for a company-specific positive or negative operating thesis. Why now: There is no usable 'why now' beyond possible strategic relevance to optical communications. The reviewed sources provide no after-recent evidence window evidence to confirm current status. Caveats: Phase-2 rationale references, but the reviewed sources does not include its or article summary. Relations marked context-only cannot be used as counterparty propagation evidence. Coverage debug shows zero evidence after recent evidence window. |
| 131 | Azista Industries Private Limited lowweak | Opp 3 Risk 2 | Thesis: The risk is that technical demonstration does not confirm scalable commercial adoption, contracts, or follow-on funding, and none of those are evidenced in the kept reviewed sources rows. Why now: The only support cited is article in the membership rationale. Because the company coverage report shows zero articles after recent evidence window and zero evidence after recent evidence window, there is no robust timing catalyst beyond the historical demonstration narrative. Caveats: Single-article support only, and not available as active evidence. No direct evidence on customer conversion, regulatory adoption, or funding. Private-company visibility is limited in these reviewed sources. |
| 132 | Azista Space lowweak | Opp 2 Risk 2 | Thesis: Risk is mostly uncertainty from minimal coverage: only one article was considered and zero evidence were available after recent evidence window, so durability, backlog, and execution status are unverified here. Why now: Why now is weak because there is no surviving 90-day evidence row in the reviewed sources to establish recency or momentum. Caveats: Only membership rationale is available; no citeable direct evidence with are provided. Single-article universe increases fragility of inference. |
| 133 | Beijing Guodian High-Tech Technology Co lowweak | Opp 4 Risk 2 | Thesis: No direct adverse evidence is provided in the reviewed sources; main risk is limited visibility into commercialization and scale from the single referenced article. Why now: The implied catalyst is the pilot-program approval, but the reviewed sources provide no retained article summary or timestamped evidence row beyond the membership rationale. Caveats: Phase2 membership rationale references: but the actual summary/evidence are absent. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Opportunity score is restrained because approval alone is described in rationale but not directly evidenced here. |
| 134 | Bellatrix Aerospace lowweak | Opp 3 Risk 2 | Thesis: Risk is primarily execution and verification uncertainty because the reviewed sources have zero available evidence after recent evidence window, so no current milestone, financing, or contract confirmation is available. Why now: Why now is only moderate in theory because propulsion/platform partnerships can matter over a 1-year-plus horizon, but these reviewed sources does not provide recency-anchored evidence after recent evidence window. Caveats: No direct evidence with available for citation. Technology differentiation is only inferred from membership rationale and is not independently corroborated in available evidence. |
| 135 | Blackstar Orbital lowweak | Opp 2 Risk 2 | Thesis: The main risk is evidence quality: the reviewed sources itself says the evidence is mostly partnership context and lacks direct company-specific operating detail, which weakens any durable 1 year+ thesis. There is still no material adverse event available after recent evidence window. Why now: No near-term or durable catalyst can be established from retained evidence because coverage debug shows zero article IDs and zero evidence after recent evidence window. Caveats: No are provided for the cited support articles in the reviewed sources. The reviewed sources explicitly characterizes the evidence as mostly partnership context rather than direct operating detail. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. |
| 136 | Boeing highstrong | Opp 8 Risk 2 | Thesis: Source-specific risk is low because there is no available direct adverse evidence tied to Boeing's space thesis in this screen. The main offset is that the contract contributes to a long-cycle program with delivery beginning in 2031, so near-term financial realization is likely gradual rather than immediate, but that is not a negative event Why now: Why now is strong because the contract was reported on June 23-25, 2026, making it recent within the 90-day recent evidence window, and it represents a fresh, material U.S. defense-space award with multiyear strategic relevance Evidence
Caveats: Some corroborating rows are supporting article context and should not be overcounted as independent confirmation. Program financial benefits may phase in over a long cycle given first delivery timing in 2031. |
| 137 | Brightside Group S.A. lowweak | Opp 2 Risk 2 | Thesis: Risk is modest due to lack of current corroborating evidence rather than any adverse development. The reviewed sources contain no direct negative evidence. Why now: Why now is weak because no representative article or direct evidence survives in the ranking fields after recent evidence window; only membership rationale references without surfaced article content. Caveats: No direct within the recent evidence window evidence is available in ranking fields. Membership rationale alone is weaker than surfaced company-specific event evidence. No negative thesis is supportable from the reviewed sources. |
| 138 | CAS Space lowweak | Opp 2 Risk 2 | Thesis: The same rationale says there is little direct company-specific detail beyond inclusion in that group. Without available direct evidence after recent evidence window, the main risk is thesis fragility and inability to verify the claimed IPO/pre-IPO progression. Why now: There is no verified current catalyst in retained evidence. IPO/pre-IPO framing could matter on a 1 year+ horizon, but recency and milestone state cannot be confirmed here because no dated evidence are available after recent evidence window. Caveats: No are provided for the cited support articles in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. IPO/pre-IPO mention is only in reviewed sources rationale, not in retained direct evidence. |
| 139 | Casimir Inc. lowweak | Opp 1 Risk 2 | Thesis: Casimir carries above-peer evidence risk in this screen because the sole cited support is described in the phase2 rationale as blog commentary, and the business fit to the target cohort is explicitly questioned. That weak grounding raises the risk of over-interpreting the financing mention. Why now: There is no available article summary or evidence row after recent evidence window, so the only 'why now' is the uncitable phase2 statement about a seed round referenced by article id: without. Caveats: The reviewed sources itself says the support article is blog commentary, weakening source quality. No citable or summary is provided for the referenced article id No evidence were available after recent evidence window in the served reviewed sources. |
| 140 | constellr mediummedium | Opp 5 Risk 2 | Thesis: Risk remains moderate because the evidence is still supporting article context rather than direct company disclosures about backlog, margins, or contracted demand, and no negative evidence is available. Execution risk remains around converting first-launch and funding momentum into durable commercial scale. Why now: Why now is relatively strongest here because the retained evidence is within the 90-day recent evidence window and dated April 16, 2026, summarizing recent business-state milestones including a first satellite launch in January 2025 and a Series A closed in February 2026. Evidence
Caveats: Evidence is external article context, not a direct company filing or contract announcement. |